JP2019047818A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019047818A5 JP2019047818A5 JP2018233311A JP2018233311A JP2019047818A5 JP 2019047818 A5 JP2019047818 A5 JP 2019047818A5 JP 2018233311 A JP2018233311 A JP 2018233311A JP 2018233311 A JP2018233311 A JP 2018233311A JP 2019047818 A5 JP2019047818 A5 JP 2019047818A5
- Authority
- JP
- Japan
- Prior art keywords
- rodent
- sirpα
- gene
- human
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000283984 Rodentia Species 0.000 claims 62
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims 56
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims 26
- 210000004027 cell Anatomy 0.000 claims 25
- 108700024394 Exon Proteins 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000003834 intracellular effect Effects 0.000 claims 4
- 229940000406 drug candidate Drugs 0.000 claims 3
- 206010057249 Phagocytosis Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 2
- 230000008782 phagocytosis Effects 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000001671 embryonic stem cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361881261P | 2013-09-23 | 2013-09-23 | |
| US61/881,261 | 2013-09-23 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016544055A Division JP6453893B2 (ja) | 2013-09-23 | 2014-09-23 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020026122A Division JP6875573B2 (ja) | 2013-09-23 | 2020-02-19 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019047818A JP2019047818A (ja) | 2019-03-28 |
| JP2019047818A5 true JP2019047818A5 (enExample) | 2020-02-27 |
| JP6665269B2 JP6665269B2 (ja) | 2020-03-13 |
Family
ID=51663510
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016544055A Active JP6453893B2 (ja) | 2013-09-23 | 2014-09-23 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
| JP2018233311A Active JP6665269B2 (ja) | 2013-09-23 | 2018-12-13 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
| JP2020026122A Active JP6875573B2 (ja) | 2013-09-23 | 2020-02-19 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
| JP2021072857A Active JP7149370B2 (ja) | 2013-09-23 | 2021-04-22 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016544055A Active JP6453893B2 (ja) | 2013-09-23 | 2014-09-23 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020026122A Active JP6875573B2 (ja) | 2013-09-23 | 2020-02-19 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
| JP2021072857A Active JP7149370B2 (ja) | 2013-09-23 | 2021-04-22 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
Country Status (28)
| Country | Link |
|---|---|
| US (9) | US9193977B2 (enExample) |
| EP (5) | EP4635977A3 (enExample) |
| JP (4) | JP6453893B2 (enExample) |
| KR (2) | KR102370419B1 (enExample) |
| CN (2) | CN108441497B (enExample) |
| AU (3) | AU2014321187B2 (enExample) |
| CA (1) | CA2925564C (enExample) |
| CY (1) | CY1121410T1 (enExample) |
| DK (4) | DK3434101T5 (enExample) |
| ES (4) | ES2624614T3 (enExample) |
| FI (2) | FI3434101T3 (enExample) |
| HR (3) | HRP20251062T1 (enExample) |
| HU (3) | HUE072332T2 (enExample) |
| IL (4) | IL297607B2 (enExample) |
| LT (3) | LT3175706T (enExample) |
| MX (1) | MX368931B (enExample) |
| NZ (1) | NZ717817A (enExample) |
| PH (1) | PH12016500342A1 (enExample) |
| PL (3) | PL3434101T3 (enExample) |
| PT (4) | PT3175706T (enExample) |
| RS (3) | RS67091B1 (enExample) |
| RU (2) | RU2018136614A (enExample) |
| SG (3) | SG10201902547SA (enExample) |
| SI (3) | SI3434101T1 (enExample) |
| SM (3) | SMT202500280T1 (enExample) |
| TR (1) | TR201901782T4 (enExample) |
| WO (1) | WO2015042557A1 (enExample) |
| ZA (1) | ZA201601138B (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4502152A3 (en) | 2009-10-06 | 2025-04-30 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
| SG10202008003VA (en) | 2011-02-15 | 2020-10-29 | Regeneron Pharma | Humanized m-csf mice |
| FI2892330T3 (fi) | 2012-09-07 | 2023-03-25 | Univ Yale | Geneettisesti muokattuja hiiriä ja menetelmiä niiden käyttämiseksi |
| MX377561B (es) | 2012-11-05 | 2025-03-10 | Regeneron Pharma | Animales no humanos genéticamente modificados y métodos de uso de los mismos. |
| TR201901782T4 (tr) * | 2013-09-23 | 2019-03-21 | Regeneron Pharma | İnsanlaştirilmiş bi̇r si̇nyal düzenleyi̇ci̇ protei̇n geni̇ne sahi̇p olan i̇nsan dişi hayvanlar. |
| ES2613379T3 (es) | 2013-10-15 | 2017-05-24 | Regeneron Pharmaceuticals, Inc. | Animales con IL-15 humanizada |
| CA2929846C (en) | 2013-11-19 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| CN111690052B (zh) | 2014-04-08 | 2024-06-04 | 瑞泽恩制药公司 | 具有人源化FC-γ受体的非人动物 |
| NO2785538T3 (enExample) | 2014-05-07 | 2018-08-04 | ||
| MX2016014995A (es) | 2014-05-19 | 2017-03-31 | Regeneron Pharma | Animales no humanos geneticamente modificados que expresan eritropoyetina de humano. |
| IL287519B2 (en) | 2014-06-19 | 2024-01-01 | Regeneron Pharma | Non-human animals having a humanized programmed cell death 1 gene |
| RU2726446C2 (ru) | 2014-11-24 | 2020-07-14 | Регенерон Фармасьютикалз, Инк. | Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3 |
| HUE064960T2 (hu) | 2014-12-05 | 2024-04-28 | Regeneron Pharma | Differenciációs 47 gén humanizált klasztert tartalmazó nem-humán állatok |
| CN113412818B (zh) | 2014-12-09 | 2022-11-04 | 瑞泽恩制药公司 | 具有人源化分化簇274基因的非人动物 |
| ES2950399T3 (es) * | 2015-04-13 | 2023-10-09 | Regeneron Pharma | Ratones humanizados Sirpa-IL15 insertados y métodos de uso de los mismos |
| CN104904661B (zh) * | 2015-06-05 | 2018-07-24 | 杭州正因生物技术有限公司 | 一种人源化小鼠 |
| AU2016304794B2 (en) | 2015-08-07 | 2021-07-15 | ALX Oncology Inc. | Constructs having a SIRP-alpha domain or variant thereof |
| WO2017087780A1 (en) | 2015-11-20 | 2017-05-26 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized lymphocyte-activation gene 3 |
| SG11201806176PA (en) | 2016-02-04 | 2018-08-30 | Regeneron Pharma | Non-human animals having an engineered angptl8 gene |
| DK3422845T3 (da) | 2016-02-29 | 2021-08-30 | Regeneron Pharma | Gnavere med et humaniseret tmprss-gen |
| CN108467873B (zh) | 2017-03-17 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用 |
| CN108588126B (zh) | 2017-03-31 | 2020-04-10 | 北京百奥赛图基因生物技术有限公司 | Cd47基因人源化改造动物模型的制备方法及应用 |
| WO2018177441A1 (en) * | 2017-03-31 | 2018-10-04 | Beijing Biocytogen Co., Ltd | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα |
| CN109136261B (zh) | 2017-06-19 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化cd28基因改造动物模型的制备方法及应用 |
| WO2018233608A1 (en) * | 2017-06-19 | 2018-12-27 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric cd28 |
| KR20200033259A (ko) | 2017-07-31 | 2020-03-27 | 리제너론 파마슈티칼스 인코포레이티드 | 생체내에서 CRISPR/Cas-매개된 파괴 또는 삭제 및 외인성 도너 핵산과의 CRISPR/Cas-유도된 재조합을 평가하기 위한 방법 및 조성물 |
| CN110891420B (zh) | 2017-07-31 | 2022-06-03 | 瑞泽恩制药公司 | Cas转基因小鼠胚胎干细胞和小鼠及其应用 |
| US20190098879A1 (en) * | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | Non-Human Animals Comprising A Humanized TTR Locus And Methods Of Use |
| JP7361031B2 (ja) | 2017-11-30 | 2023-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物 |
| EP3592140A1 (en) | 2018-03-19 | 2020-01-15 | Regeneron Pharmaceuticals, Inc. | Transcription modulation in animals using crispr/cas systems |
| IL314733A (en) | 2018-03-26 | 2024-10-01 | Regeneron Pharma | Humanized rodents for testing therapeutic agents |
| SG11202012338QA (en) | 2018-07-10 | 2021-01-28 | Univ Kobe Nat Univ Corp | ANTI-SIRPa ANTIBODY |
| HRP20240999T1 (hr) | 2018-07-16 | 2024-10-25 | Regeneron Pharmaceuticals, Inc. | Glodavački modeli bolesti ditra i njihova upotreba |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020160285A1 (en) * | 2019-02-01 | 2020-08-06 | The Board Of Trustees Of The Leland Stanford Junior University | SIRPα EXPRESSION ON T CELLS IS A BIOMARKER FOR FUNCTIONAL T CELLS DURING EXHAUSTION |
| KR102661779B1 (ko) | 2019-04-04 | 2024-04-30 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 응고 인자 12 좌위를 포함하는 비-인간 동물 |
| CN114126648A (zh) | 2019-05-31 | 2022-03-01 | Alx肿瘤生物技术公司 | 用SIRPα Fc融合体组合免疫检查点抑制剂治疗癌症的方法 |
| US11891618B2 (en) | 2019-06-04 | 2024-02-06 | Regeneron Pharmaceuticals, Inc. | Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use |
| MX2021015122A (es) | 2019-06-07 | 2022-04-06 | Regeneron Pharma | Animales no humanos que comprenden un locus de albumina humanizado. |
| CN121243368A (zh) | 2019-11-27 | 2026-01-02 | Alx肿瘤生物技术公司 | 用于治疗癌症的组合疗法 |
| US20230058049A1 (en) * | 2019-12-31 | 2023-02-23 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | GENETICALLY MODIFIED IMMUNODEFICIENT NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPa/CD47 |
| WO2021154791A1 (en) | 2020-01-28 | 2021-08-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized pnpla3 locus and methods of use |
| JP7765403B2 (ja) | 2020-04-21 | 2025-11-06 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｃｘｃｌ１３遺伝子を有する非ヒト動物 |
| JP2024500153A (ja) * | 2020-12-21 | 2024-01-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｔｓｌｐ遺伝子、ヒト化ｔｓｌｐ受容体遺伝子、及び／又はヒト化ｉｌ７ｒａ遺伝子を有する非ヒト動物 |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| KR20240117571A (ko) | 2021-12-08 | 2024-08-01 | 리제너론 파마슈티칼스 인코포레이티드 | 돌연변이 마이오실린 질환 모델 및 이의 용도 |
| WO2023143341A1 (en) * | 2022-01-25 | 2023-08-03 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric nkp46 |
| IL318159A (en) | 2022-07-19 | 2025-03-01 | Regeneron Pharma | Genetically modified animal model and its use to model the human immune system |
| EP4593590A1 (en) | 2022-09-29 | 2025-08-06 | Regeneron Pharmaceuticals, Inc. | Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes |
| KR20260025082A (ko) | 2023-06-16 | 2026-02-23 | 리제너론 파마슈티칼스 인코포레이티드 | 벡터, 유전자 변형 세포, 및 그것을 포함하는 유전자 변형 비인간 동물 |
| US20250255282A1 (en) | 2024-02-08 | 2025-08-14 | Regeneron Pharmaceuticals, Inc. | Vectors, genetically modified cells, and genetically modified non-human animals comprising the same |
| WO2025212991A1 (en) | 2024-04-05 | 2025-10-09 | Regeneron Pharmaceuticals, Inc. | Rodent models of disease |
| WO2025250495A1 (en) | 2024-05-28 | 2025-12-04 | Regeneron Pharmaceuticals, Inc. | Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5149635A (en) * | 1986-09-12 | 1992-09-22 | Abbott Biotech, Inc. | Messenger RNA stabilization in animal cells |
| CZ294615B6 (cs) * | 1997-09-12 | 2005-02-16 | Apotech R & D Sa | Léčivo obsahující protilátky reaktivní s polypeptidovým ligandem APRIL pro léčení rakoviny |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ES2587344T3 (es) * | 2003-12-24 | 2016-10-24 | Novo Nordisk A/S | Ratón transgénico que comprende un polinucleótido que codifica C5aR humano o humanizado |
| ES2463476T3 (es) | 2004-10-19 | 2014-05-28 | Regeneron Pharmaceuticals, Inc. | Método para generar un ratón homocigótico para una modificación genética |
| EP1907566A4 (en) * | 2005-05-27 | 2008-12-10 | Memory Pharm Corp | VECTORS FOR TRANSGENIC MORBUS ALZHEIMER MOUSE MODEL AND USES THEREOF |
| US20070028316A1 (en) * | 2005-06-02 | 2007-02-01 | Xiaoxia Li | Transgenic non-human Act1-deficient mammals and uses thereof |
| EP2573112A1 (en) * | 2007-10-11 | 2013-03-27 | The Hospital For Sick Children | Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
| TWI476280B (zh) | 2008-03-07 | 2015-03-11 | Regeneron Pharma | 來自二倍體宿主胚胎注射之ｅｓ－細胞衍生的老鼠 |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| EP4502152A3 (en) | 2009-10-06 | 2025-04-30 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
| EP2618656B1 (en) * | 2010-09-20 | 2018-06-20 | Yale University, Inc. | HUMAN SIRPalpha TRANSGENIC ANIMALS AND THEIR METHODS OF USE |
| ES2680636T3 (es) * | 2011-02-14 | 2018-09-10 | Revivicor Inc. | Cerdos genéticamente modificados para xenotrasplante de xenoinjertos vascularizados y derivados de los mismos |
| SG10202008003VA (en) * | 2011-02-15 | 2020-10-29 | Regeneron Pharma | Humanized m-csf mice |
| SMT202200205T1 (it) | 2011-10-28 | 2022-07-21 | Regeneron Pharma | Topi geneticamente modificati che esprimono molecole chimeriche del complesso maggiore di istocompatibilità (mhc) ii |
| CN108866101A (zh) * | 2011-10-28 | 2018-11-23 | 瑞泽恩制药公司 | 人源化il-6和il-6受体 |
| SMT201900478T1 (it) | 2011-10-28 | 2019-09-09 | Regeneron Pharma | Topi con complesso maggiore di istocompatibilita' geneticamente modificati |
| US8962913B2 (en) | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
| FI2892330T3 (fi) | 2012-09-07 | 2023-03-25 | Univ Yale | Geneettisesti muokattuja hiiriä ja menetelmiä niiden käyttämiseksi |
| MX377561B (es) | 2012-11-05 | 2025-03-10 | Regeneron Pharma | Animales no humanos genéticamente modificados y métodos de uso de los mismos. |
| CN111484999B (zh) | 2013-02-20 | 2024-10-25 | 瑞泽恩制药公司 | 人源化的t细胞共受体的小鼠 |
| EP3699190B9 (en) | 2013-02-22 | 2023-10-04 | Regeneron Pharmaceuticals, Inc. | Murine cell expressing humanized major histocompatibility complex |
| TR201901782T4 (tr) * | 2013-09-23 | 2019-03-21 | Regeneron Pharma | İnsanlaştirilmiş bi̇r si̇nyal düzenleyi̇ci̇ protei̇n geni̇ne sahi̇p olan i̇nsan dişi hayvanlar. |
| CA2984413A1 (en) * | 2015-04-30 | 2016-11-03 | Institute Of Immunology Co., Ltd. | Transgenic non-human animal expressing human specific molecule and human fc.gamma. receptor family |
-
2014
- 2014-09-23 TR TR2019/01782T patent/TR201901782T4/tr unknown
- 2014-09-23 KR KR1020167008334A patent/KR102370419B1/ko active Active
- 2014-09-23 PL PL18192264.2T patent/PL3434101T3/pl unknown
- 2014-09-23 SI SI201432041T patent/SI3434101T1/sl unknown
- 2014-09-23 PL PL16206491T patent/PL3175706T3/pl unknown
- 2014-09-23 SI SI201431078T patent/SI3175706T1/sl unknown
- 2014-09-23 CN CN201810267662.3A patent/CN108441497B/zh active Active
- 2014-09-23 RS RS20250788A patent/RS67091B1/sr unknown
- 2014-09-23 LT LTEP16206491.9T patent/LT3175706T/lt unknown
- 2014-09-23 PL PL23185050.4T patent/PL4269430T3/pl unknown
- 2014-09-23 SG SG10201902547SA patent/SG10201902547SA/en unknown
- 2014-09-23 ES ES14781783.7T patent/ES2624614T3/es active Active
- 2014-09-23 NZ NZ717817A patent/NZ717817A/en unknown
- 2014-09-23 DK DK18192264.2T patent/DK3434101T5/da active
- 2014-09-23 CN CN201480051997.1A patent/CN105592695B/zh active Active
- 2014-09-23 FI FIEP18192264.2T patent/FI3434101T3/fi active
- 2014-09-23 WO PCT/US2014/056910 patent/WO2015042557A1/en not_active Ceased
- 2014-09-23 US US14/493,745 patent/US9193977B2/en active Active
- 2014-09-23 EP EP25183430.5A patent/EP4635977A3/en active Pending
- 2014-09-23 EP EP16206491.9A patent/EP3175706B1/en active Active
- 2014-09-23 ES ES16206491T patent/ES2710282T3/es active Active
- 2014-09-23 SI SI201432112T patent/SI4269430T1/sl unknown
- 2014-09-23 LT LTEP18192264.2T patent/LT3434101T/lt unknown
- 2014-09-23 DK DK14781783.7T patent/DK2922394T3/en active
- 2014-09-23 EP EP14781783.7A patent/EP2922394B1/en active Active
- 2014-09-23 RU RU2018136614A patent/RU2018136614A/ru not_active Application Discontinuation
- 2014-09-23 LT LTEP23185050.4T patent/LT4269430T/lt unknown
- 2014-09-23 EP EP23185050.4A patent/EP4269430B1/en active Active
- 2014-09-23 RS RS20230816A patent/RS64573B1/sr unknown
- 2014-09-23 CA CA2925564A patent/CA2925564C/en active Active
- 2014-09-23 FI FIEP23185050.4T patent/FI4269430T3/fi active
- 2014-09-23 MX MX2016003636A patent/MX368931B/es active IP Right Grant
- 2014-09-23 PT PT16206491T patent/PT3175706T/pt unknown
- 2014-09-23 ES ES18192264T patent/ES2959333T3/es active Active
- 2014-09-23 HR HRP20251062TT patent/HRP20251062T1/hr unknown
- 2014-09-23 SM SM20250280T patent/SMT202500280T1/it unknown
- 2014-09-23 HU HUE23185050A patent/HUE072332T2/hu unknown
- 2014-09-23 DK DK23185050.4T patent/DK4269430T3/da active
- 2014-09-23 PT PT231850504T patent/PT4269430T/pt unknown
- 2014-09-23 EP EP18192264.2A patent/EP3434101B1/en active Active
- 2014-09-23 HR HRP20231121TT patent/HRP20231121T1/hr unknown
- 2014-09-23 PT PT181922642T patent/PT3434101T/pt unknown
- 2014-09-23 SG SG11201601184UA patent/SG11201601184UA/en unknown
- 2014-09-23 RU RU2016110462A patent/RU2671166C2/ru active
- 2014-09-23 IL IL297607A patent/IL297607B2/en unknown
- 2014-09-23 SG SG10201801326PA patent/SG10201801326PA/en unknown
- 2014-09-23 ES ES23185050T patent/ES3037239T3/es active Active
- 2014-09-23 SM SM20230287T patent/SMT202300287T1/it unknown
- 2014-09-23 PT PT147817837T patent/PT2922394T/pt unknown
- 2014-09-23 KR KR1020227006825A patent/KR102407354B1/ko active Active
- 2014-09-23 DK DK16206491.9T patent/DK3175706T3/en active
- 2014-09-23 JP JP2016544055A patent/JP6453893B2/ja active Active
- 2014-09-23 RS RS20190162A patent/RS58365B1/sr unknown
- 2014-09-23 HU HUE18192264A patent/HUE063376T2/hu unknown
- 2014-09-23 HU HUE16206491A patent/HUE042412T2/hu unknown
- 2014-09-23 SM SM20190067T patent/SMT201900067T1/it unknown
- 2014-09-23 AU AU2014321187A patent/AU2014321187B2/en active Active
- 2014-10-17 US US14/516,606 patent/US9127292B2/en active Active
-
2015
- 2015-10-14 US US14/882,531 patent/US9462794B2/en active Active
-
2016
- 2016-02-18 IL IL244187A patent/IL244187B/en active IP Right Grant
- 2016-02-18 ZA ZA2016/01138A patent/ZA201601138B/en unknown
- 2016-02-19 PH PH12016500342A patent/PH12016500342A1/en unknown
- 2016-09-13 US US15/263,916 patent/US9700027B2/en active Active
-
2017
- 2017-06-06 US US15/615,298 patent/US9901083B2/en active Active
-
2018
- 2018-01-10 US US15/866,632 patent/US10206379B2/en active Active
- 2018-11-12 IL IL262958A patent/IL262958A/en active IP Right Grant
- 2018-12-13 JP JP2018233311A patent/JP6665269B2/ja active Active
-
2019
- 2019-01-03 US US16/238,589 patent/US10426146B2/en active Active
- 2019-02-05 HR HRP20190227TT patent/HRP20190227T1/hr unknown
- 2019-02-07 CY CY20191100163T patent/CY1121410T1/el unknown
- 2019-08-15 US US16/541,334 patent/US11019810B2/en active Active
-
2020
- 2020-02-19 JP JP2020026122A patent/JP6875573B2/ja active Active
- 2020-11-12 IL IL278679A patent/IL278679B2/en unknown
- 2020-12-08 AU AU2020286187A patent/AU2020286187B2/en active Active
-
2021
- 2021-04-22 JP JP2021072857A patent/JP7149370B2/ja active Active
- 2021-04-27 US US17/241,171 patent/US12161097B2/en active Active
-
2024
- 2024-09-02 AU AU2024216527A patent/AU2024216527A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019047818A5 (enExample) | ||
| Krusche et al. | Desmoglein 2 mutant mice develop cardiac fibrosis and dilation | |
| Banerjee et al. | Targeted ablation of nesprin 1 and nesprin 2 from murine myocardium results in cardiomyopathy, altered nuclear morphology and inhibition of the biomechanical gene response | |
| Guo et al. | Keratin 14-dependent disulfides regulate epidermal homeostasis and barrier function via 14-3-3σ and YAP1 | |
| Khalil et al. | Fibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis | |
| WO2015042557A4 (en) | Non-human animals having a humanized signal-regulatory protein gene | |
| Kim et al. | S100A9 knockout decreases the memory impairment and neuropathology in crossbreed mice of Tg2576 and S100A9 knockout mice model | |
| JP2018500012A5 (enExample) | ||
| HRP20200613T1 (hr) | Neljudske životinje koje imaju humanizirani gen 1 za programiranu staničnu smrt | |
| JP2017514501A5 (enExample) | ||
| CN113940309B (zh) | 一种慢性萎缩性胃炎病变的模拟方法及小鼠造模鉴定方法 | |
| Leclère et al. | Otoferlin as a multirole Ca2+ signaling protein: from inner ear synapses to cancer pathways | |
| JP2017500854A (ja) | ポリペプチド、核酸およびその使用 | |
| Du et al. | A point mutation (R192H) in the C-terminus of human cardiac troponin I causes diastolic dysfunction in transgenic mice | |
| Wang et al. | Translocator protein (Tspo) gene promoter-driven green fluorescent protein synthesis in transgenic mice: an in vivo model to study Tspo transcription | |
| CN102712687A (zh) | 作为补体激活的抑制剂的masp同种型 | |
| JP2019506897A5 (enExample) | ||
| JPWO2002039813A1 (ja) | Ｐｄ−１欠損マウスおよびその用途 | |
| CN102176914B (zh) | 用于诊断和治疗癌症的vhz | |
| Sanematsu et al. | Fhod1, an actin‐organizing formin family protein, is dispensable for cardiac development and function in mice | |
| CN106994185A (zh) | Tie2对视网膜及其他组织中静脉血管的保护作用及应用 | |
| CN113817769B (zh) | 射血分数保留的心衰动物模型的构建方法及应用 | |
| Zupkovitz et al. | Phylogenetic analysis and expression profiling of the Klotho gene family in the short-lived African killifish Nothobranchius furzeri | |
| WO2002064731A2 (fr) | Sequences impliquees dans les phenomenes de suppression tumorale reversion tumorale apoptose et/ou resistance aux virus et leur utilisation comme medicaments | |
| JP2023543232A (ja) | ヘッジホッグシグナル伝達経路の活性化のための強力な結合剤 |